Antidepressants are among the most prescribed types of drugs in the US,1 despite the fact that many of them have also been linked to violence against self and others.
In 2004, the US Food and Drug Administration (FDA) revised2 the labeling requirements for antidepressant medications (SSRIs and others), warning that:
“Antidepressants increased the risk compared to placebo of suicidal thinking and behavior (suicidality) in children, adolescents, and young adults in short-term studies of major depressive disorder (MDD) and other psychiatric disorders.
Anyone considering the use of [Insert established name] or any other antidepressant in a child, adolescent, or young adult must balance this risk with the clinical need.”
These labeling revisions were in large part driven by lawsuits in which pharmaceutical companies were forced to reveal previously undisclosed drug data.